GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on November 26, 2019. The document serves as a Block Listing Six Monthly Return detailing the status of the company's equity incentive schemes for the period from May 1, 2019, to October 31, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory report on share scheme balances and does not contain financial performance data.
Material Changes in Share Schemes
The filing reports the following movements in unallotted securities across four specific schemes during the reporting period:
- 2009 Deferred Annual Bonus Plan: No securities were issued or allotted. The balance of unallotted securities remained at 153,724.
- 2009 Share Option Plan - Ordinary Shares: 429,913 securities were issued/allotted. The unallotted balance decreased from 1,265,008 to 835,095.
- 2009 Share Option Plan - ADS: 519,880 securities were issued/allotted. The unallotted balance decreased from 5,911,296 to 5,391,416.
- Share Save Plan 2012: 181,084 securities were issued/allotted. The unallotted balance decreased from 2,326,896 to 2,145,812.
No increases were applied for in any of the block schemes during this period.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory reporting of share scheme mechanics.
Key Facts for Investor Verification
- Verify the total number of shares issued under the 2009 Share Option Plans (Ordinary and ADS) to assess potential dilution impact.
- Confirm the remaining pool of unallotted shares available for future grants under the 2009 Deferred Annual Bonus Plan and Share Save Plan 2012.
- Note that no new share blocks were authorized for any scheme during the six-month period ending October 31, 2019.